

Protocol for Inactivated Influenza Vaccines (IIV), Recombinant Influenza Vaccines (RIV), and Live Attenuated Influenza Vaccine (LAIV)

1. What's New

- A. The West Coast Health Alliance (WCHA) is issuing immunization recommendations for the 2025-2026 respiratory virus season. These recommendations are informed by trusted national medical organizations, including [American Academy of Pediatrics](#) (AAP), the [American College of Obstetricians and Gynecologists](#) (ACOG), and the [American Academy of Family Physicians](#) (AAFP). The WCHA believes that all recommended immunizations should be accessible to the people of our states.
- B. All cell-culture-based inactivated or recombinant-based influenza vaccines for use in the 2025-2026 influenza season¹ (Northern Hemisphere) contain the following:
 - i) A/Wisconsin/67/2022 (H1N1)-like virus
 - ii) A/District of Columbia/27/2023 (H3N2)-like virus (updated)
 - iii) B/Austria/1359417/2021 (B/Victoria lineage)-like virus
- C. All egg-based inactivated influenza vaccines (LAIV3 [FluMist®]) for use in the 2025-2026 influenza season¹ (Northern Hemisphere) contain the following:
 - i) A/Victoria/4897/2022 (H1N1)-like virus
 - ii) A/Croatia/Y10136RV/2023 (H3N2)-like virus (updated)
 - iii) B/Austria/1359417/2021 (B/Victoria lineage)-like virus
- D. Individuals 6 months of age and older should receive an age-appropriate influenza vaccination annually.²

2. Immunization Protocol

- A. Administer a 0.25-mL or 0.5-mL dose, IM, of an appropriate influenza vaccine, to persons ≥ 6 months of age based on the patient's age and the formulation being used.
- B. Administer a 0.2-ml dose, Intranasally, if appropriate to persons ≥ 2 years of age.
- C. May be given with all ACIP- and WCHA-recommended child and adult vaccinations, including COVID-19 vaccines.

3. Vaccine Schedule ¹


	Influenza vaccine
Children	All ≥ 6 months*
Pregnancy	All planning, pregnant, postpartum, and lactating
Adults	All ≥ 18 years

*See flow chart in Section 4 for determining whether 1 or 2 doses is appropriate.

Protocol for Inactivated Influenza Vaccines (IIV), Recombinant Influenza Vaccines (RIV), and Live Attenuated Influenza Vaccine (LAIV)

4. Additional Considerations for Use ²⁻¹²

- A. Persons with immunocompromising conditions should receive an age-appropriate IIV or RIV, with the exception of solid organ transplant recipients.
- B. Immune response to influenza vaccines might be blunted in persons with some conditions, such as persons with congenital immune deficiencies, persons receiving cancer chemotherapy, and persons receiving immunosuppressive medications.
- C. Influenza vaccine should be administered beginning at least 6 months after Hematopoietic Stem Cell Transplant (HSCT), and annually thereafter for the life of the patient. A dose of vaccine can be given as soon as 4 months after the transplant, and a second dose should be considered in this situation. Do not use live influenza vaccine in this population.
- D. Children < 9 years of age receiving flu vaccine for the first time need 2 doses, separated by at least 28 days. Children who receive the first dose at age 8 years and turn 9 during flu season should receive the 2nd dose in the same season.



5. Pregnancy and Lactation ²⁻¹¹

- A. All planning, pregnant, postpartum, and lactating may receive a 2025-2026 influenza vaccine.
- B. See current prescribing information additional considerations regarding pregnancy and lactation.

6. Warnings and Precautions ²⁻¹²

- A. Severe allergic reaction (e.g., anaphylaxis) to a previous dose or to any vaccine component, including egg protein.
- B. Persons with immunocompromising conditions should receive an age appropriate IIV or RIV4. Immune response to influenza vaccines might be blunted in persons with some conditions, such as persons with congenital immune deficiencies, persons receiving cancer chemotherapy, and persons receiving immunosuppressive medications.¹²
- C. Hematopoietic Stem Cell Transplant (HSCT) recipients: Influenza vaccine should be administered beginning at least 6 months after HSCT and annually thereafter for the life of the patient. A dose of vaccine can be given as soon as 4 months after the transplant, but a second dose should be considered in this situation. Do not use live influenza vaccine in this population.¹²
- D. See current prescribing information for more details about warnings, precautions, formulation, and contents.

Protocol for Inactivated Influenza Vaccines (IIV), Recombinant Influenza Vaccines (RIV), and Live Attenuated Influenza Vaccine (LAIV)

7. Contraindications ³⁻¹¹

- A. If Guillain-Barré syndrome (GBS) has occurred after receipt of a prior influenza vaccine, especially within 6 weeks, the decision to give influenza vaccine should be based on careful consideration of the potential benefits and risks.
- B. A history of severe allergic reaction to a previous dose of any influenza vaccine or any component of the vaccine, excluding egg protein. For persons with severe egg allergy, refer Section 6.
- C. See current prescribing information for more details about contraindications.

8. Storage and Handling ³⁻¹¹

- A. Store all drugs at the proper temperature according to manufacturer's published guidelines (pursuant to FDA package insert).
- B. See current prescribing information for more details about storage and handling.
- C. All clinics and pharmacies enrolled with the Vaccines for Children (VFC) Program must immediately report any storage and handling deviations to the Oregon Immunization Program at 971-673-4VFC (4823).

9. References

1. Dugan V. 2024-25 Influenza Season Update and Seasonal Influenza Vaccine Recommendations for the 2025-26 U.S. Influenza Season. Presentation to the Advisory Committee on Immunization Practices, June 26, 2025. Available at: <https://www.cdc.gov/acip/downloads/slides-2025-06-25-26/04-dugan-influenza508.pdf>. Accessed 17 Sept. 2025.
2. West Coast Health Alliance 2025-2026 Recommendations for Respiratory Vaccines. Available at: https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/VACCINESIMMUNIZATION/GETTING_MMUNIZED/Documents/2025-26-Respiratory-Virus-Vaccine-Recommendations.pdf
3. Afluria® IIV3 2025–2026. [Package insert]. Available at: <https://www.fda.gov/media/81559/download>
4. Fluad® IIV3 (Adjuvanted) 2025 -2026. [Package insert]. Available at: www.fda.gov/media/81559/download
5. Fluarix® IIV3 2025–2026. [Package insert]. Available at: www.fda.gov/media/84804/download
6. Flublok® RIV3 2025–2026. [Package insert]. Available at: www.fda.gov/media/179778/download
7. Flucelvax® 2025–2026. [Package insert]. Available at: www.fda.gov/media/85322/download
8. FluLaval® cclIV3 2025–2026. [Package insert]. Available at: www.fda.gov/media/74537/download?attachment
9. Fluzone® High-dose IIV3 2025–2026. [Package insert]. Available at: www.fda.gov/media/139731/download
10. Fluzone® IIV3 2025–2026. [Package insert]. Available at: www.fda.gov/media/170019/download
11. Flumist® LAIV 2025-2026. [Package insert]. Available at: <https://www.fda.gov/media/180697/download>
12. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA Clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44– 100. Available at: <https://academic.oup.com/cid/article/58/3/e44/336537>.